Anti-tumor effects of canine adipose tissue-derived mesenchymal stromal cell-based interferon-β gene therapy and cisplatin in a mouse melanoma model

References

• Weatherall DJ. Scope and limitations of gene therapy. Br Med Bull. 1995;51:1–11.
   PubMedGoogle Scholar
• Dwyer RM, Kerin MJ. Mesenchymal stem cells (MSCs) and cancer: tumour specific delivery vehicles or therapeutic targets? Hum Gene Ther. 2010;21(11):1506–12.
   PubMedGoogle Scholar
• Studeny M, Marini FC, Champlin RE, Zompetta C, Fidler IJ, Andreeff M. Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer Res. 2002;62:3603–8.
   PubMed Web of Science ®Google Scholar
• Nakamizo A, Marini F, Amano T, Khan A, Studeny M, Gumin J, . Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res. 2005;65: 3307–18.
   PubMed Web of Science ®Google Scholar
• Studeny M, Marini FC, Dembinski JL, Zompetta C, Cabreira-Hansen M, Bekele BN, . Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. J Natl Cancer Inst. 2004;96:1593–603.
   PubMed Web of Science ®Google Scholar
• Pereboeva L, Curiel DT. Cellular vehicles for cancer gene therapy: current status and future potential. BioDrugs. 2004; 18:361–85.
   PubMedGoogle Scholar
• Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med. 1986;315:1650–9.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57–70.
   PubMed Web of Science ®Google Scholar
• Kern S, Eichler H, Stoeve J, Kluter H, Bieback K. Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells. 2006;24: 1294–301.
   PubMed Web of Science ®Google Scholar
• Oedayrajsingh-Varma MJ, van Ham SM, Knippenberg M, Helder MN, Klein-Nulend J, Schouten TE, . Adipose tissue-derived mesenchymal stem cell yield and growth characteristics are affected by the tissue-harvesting procedure. Cytotherapy. 2006;8:166–77.
   PubMed Web of Science ®Google Scholar
• Hui JH, Li L, Teo YH, Ouyang HW, Lee EH. Comparative study of the ability of mesenchymal stem cells derived from bone marrow, periosteum, and adipose tissue in treatment of partial growth arrest in rabbit. Tissue Eng. 2005; 11:904–12.
   PubMedGoogle Scholar
• Wigginton JM, Wiltrout RH. IL-12/IL-2 combination cytokine therapy for solid tumours: translation from bench to bedside. Expert Opin Biol Ther. 2002;2:513–24.
   PubMed Web of Science ®Google Scholar
• Sikora AG, Jaffarzad N, Hailemichael Y, Gelbard A, Stonier SW, Schluns KS, . IFN-alpha enhances peptide vaccine-induced CD8 + T cell numbers, effector function, and antitumor activity. J Immunol. 2009;182:7398–407.
   PubMed Web of Science ®Google Scholar
• Cole BF, Gelber RD, Kirkwood JM, Goldhirsch A, Barylak E, Borden E. Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol. 1996;14:2666–73.
   PubMed Web of Science ®Google Scholar
• Spiegel RJ. The alpha interferons: clinical overview. Semin Oncol. 1987;14:1–12.
   PubMed Web of Science ®Google Scholar
• Einhorn S, Grander D. Why do so many cancer patients fail to respond to interferon therapy? J Interferon Cytokine Res. 1996;16:275–81.
   PubMed Web of Science ®Google Scholar
• Jonasch E, Haluska FG. Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. Oncologist. 2001;6:34–55.
   PubMed Web of Science ®Google Scholar
• Kirkwood JM, Ernstoff MS. Interferons in the treatment of human cancer. J Clin Oncol. 1984;2:336–52.
   PubMed Web of Science ®Google Scholar
• Chawla-Sarkar M, Leaman DW, Borden EC. Preferential induction of apoptosis by interferon (IFN)-beta compared with IFN-alpha2: correlation with TRAIL/Apo2L induction in melanoma cell lines. Clin Cancer Res. 2001;7:1821–31.
   PubMed Web of Science ®Google Scholar
• Chen Q, Gong B, Mahmoud-Ahmed AS, Zhou A, Hsi ED, Hussein M, . Apo2L/TRAIL and Bcl-2-related proteins regulate type I interferon-induced apoptosis in multiple myeloma. Blood. 2001;98:2183–92.
   PubMed Web of Science ®Google Scholar
• Morrison BH, Bauer JA, Kalvakolanu DV, Lindner DJ. Inositol hexakisphosphate kinase 2 mediates growth suppressive and apoptotic effects of interferon-beta in ovarian carcinoma cells. J Biol Chem. 2001;276:24965–70.
   PubMed Web of Science ®Google Scholar
• Horikoshi T, Fukuzawa K, Hanada N, Ezoe K, Eguchi H, Hamaoka S, . In vitro comparative study of the antitumor effects of human interferon-alpha, beta and gamma on the growth and invasive potential of human melanoma cells. J Dermatol. 1995;22:631–6.
   PubMedGoogle Scholar
• Johns TG, Mackay IR, Callister KA, Hertzog PJ, Devenish RJ, Linnane AW. Antiproliferative potencies of interferons on melanoma cell lines and xenografts: higher efficacy of interferon beta. J Natl Cancer Inst. 1992;84:1185–90.
   PubMedGoogle Scholar
• Taylor KL, Leaman DW, Grane R, Mechti N, Borden EC, Lindner DJ. Identification of interferon-beta-stimulated genes that inhibit angiogenesis in vitro. J Interferon Cytokine Res. 2008;28:733–40.
   PubMedGoogle Scholar
• Rachakatla RS, Pyle MM, Ayuzawa R, Edwards SM, Marini FC, Weiss ML, . Combination treatment of human umbilical cord matrix stem cell-based interferon-beta gene therapy and 5-fluorouracil significantly reduces growth of metastatic human breast cancer in SCID mouse lungs. Cancer Invest. 2008;26:662–70.
   PubMed Web of Science ®Google Scholar
• Rachakatla RS, Marini F, Weiss ML, Tamura M, Troyer D. Development of human umbilical cord matrix stem cell-based gene therapy for experimental lung tumors. Cancer Gene Ther. 2007;14:828–35.
   Google Scholar
• Chirino YI, Hernandez-Pando R, Pedraza-Chaverri J. Peroxynitrite decomposition catalyst ameliorates renal damage and protein nitration in cisplatin-induced nephrotoxicity in rats. BMC Pharmacol. 2004;4:20.
   PubMedGoogle Scholar
• Olaussen KA, Dunant A, Fouret P, Brambilla E, Andre F, Haddad V, . DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med. 2006;355:983–91.
   PubMed Web of Science ®Google Scholar
• Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med. 2004;350:351–60.
   PubMed Web of Science ®Google Scholar
• Balkwill F, Taylor-Papadimitriou J. Interferon affects both G1 and S + G2 in cells stimulated from quiescence to growth. Nature. 1978;274:798–800.
   PubMedGoogle Scholar
• Kopf J, Hanson C, Delle U, Weimarck A, Stierner U. Action of interferon alpha and beta on four human melanoma cell lines in vitro. Anticancer Res. 1996;16:791–8.
   PubMedGoogle Scholar
• Sidky YA, Borden EC. Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses. Cancer Res. 1987;47:5155–61.
   PubMed Web of Science ®Google Scholar
• Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD. How cells respond to interferons. Annu Rev Biochem. 1998; 67:227–64.
   PubMed Web of Science ®Google Scholar
• Gibson DF, Johnson DA, Goldstein D, Langan-Fahey SM, Borden EC, Jordan VC. Human recombinant interferon-beta SER and tamoxifen: growth suppressive effects for the human breast carcinoma MCF-7 grown in the athymic mouse. Breast Cancer Res Treat. 1993;25:141–50.
   PubMed Web of Science ®Google Scholar
• Fuertes MA, Alonso C, Perez JM. Biochemical modulation of cisplatin mechanisms of action: enhancement of antitumor activity and circumvention of drug resistance. Chem Rev. 2003;103:645–62.
   PubMed Web of Science ®Google Scholar
• Li D, Ronson B, Guo M, Liu S, Bishop JS, Van Echo DA, . Interleukin 2 gene transfer prevents NKG2D suppression and enhances antitumor efficacy in combination with cisplatin for head and neck squamous cell cancer. Cancer Res. 2002;62:4023–8.
   PubMedGoogle Scholar
• Balkwill FR, Mowshowitz S, Seilman SS, Moodie EM, Griffin DB, Fantes KH, . Positive interactions between interferon and chemotherapy due to direct tumor action rather than effects on host drug-metabolizing enzymes. Cancer Res. 1984;44:5249–55.
   PubMed Web of Science ®Google Scholar
• Mavligit GM, Charnsangavej C, Carrasco CH, Patt YZ, Benjamin RS, Wallace S. Regression of ocular melanoma metastatic to the liver after hepatic arterial chemoembolization with cisplatin and polyvinyl sponge. JAMA. 1988;260:974–6.
   PubMed Web of Science ®Google Scholar
• Aboody KS, Najbauer J, Danks MK. Stem and progenitor cell-mediated tumor selective gene therapy. Gene Ther. 2008;15:739–52.
   PubMed Web of Science ®Google Scholar
• Pisati F, Belicchi M, Acerbi F, Marchesi C, Giussani C, Gavina M, . Effect of human skin-derived stem cells on vessel architecture, tumor growth, and tumor invasion in brain tumor animal models. Cancer Res. 2007;67:3054–63.
   PubMed Web of Science ®Google Scholar
• Maestroni GJ, Hertens E, Galli P. Factor(s) from nonmacrophage bone marrow stromal cells inhibit Lewis lung carcinoma and B16 melanoma growth in mice. Cell Mol Life Sci. 1999;55:663–7.
   Web of Science ®Google Scholar
• Ohlsson LB, Varas L, Kjellman C, Edvardsen K, Lindvall M. Mesenchymal progenitor cell-mediated inhibition of tumor growth in vivo and in vitro in gelatin matrix. Exp Mol Pathol. 2003;75:248–55.
   PubMed Web of Science ®Google Scholar
• Lu YR, Yuan Y, Wang XJ, Wei LL, Chen YN, Cong C, . The growth inhibitory effect of mesenchymal stem cells on tumor cells in vitro and in vivo. Cancer Biol Ther. 2008;7:245–51.
   PubMed Web of Science ®Google Scholar
• Zhu W, Xu W, Jiang R, Qian H, Chen M, Hu J, . Mesenchymal stem cells derived from bone marrow favor tumor cell growth in vivo. Exp Mol Pathol. 2006;80: 267–74.
   PubMed Web of Science ®Google Scholar
• Kyriakou CA, Yong KL, Benjamin R, Pizzey A, Dogan A, Singh N, . Human mesenchymal stem cells (hMSCs) expressing truncated soluble vascular endothelial growth factor receptor (tsFlk-1) following lentiviral-mediated gene transfer inhibit growth of Burkitt's lymphoma in a murine model. J Gene Med. 2006;8:253–64.
   PubMed Web of Science ®Google Scholar
• Gunn WG, Conley A, Deininger L, Olson SD, Prockop DJ, Gregory CA. A crosstalk between myeloma cells and marrow stromal cells stimulates production of DKK1 and interleukin-6: a potential role in the development of lytic bone disease and tumor progression in multiple myeloma. Stem Cells. 2006;24:986–91.
   PubMed Web of Science ®Google Scholar
• Ramasamy R, Lam EW, Soeiro I, Tisato V, Bonnet D, Dazzi F. Mesenchymal stem cells inhibit proliferation and apoptosis of tumor cells: impact on in vivo tumor growth. Leukemia. 2007;21:304–10.
   PubMed Web of Science ®Google Scholar
• Khakoo AY, Pati S, Anderson SA, Reid W, Elshal MF, Rovira, II, . Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma. J Exp Med. 2006;203:1235–47.
   PubMed Web of Science ®Google Scholar
• Salmon P, Le Cotonnec JY, Galazka A, Abdul-Ahad A, Darragh A. Pharmacokinetics and pharmacodynamics of recombinant human interferon-beta in healthy male volunteers. J Interferon Cytokine Res. 1996;16:759–64.
   PubMed Web of Science ®Google Scholar
• Elzaouk L, Moelling K, Pavlovic J. Anti-tumor activity of mesenchymal stem cells producing IL-12 in a mouse melanoma model. Exp Dermatol. 2006;15:865–74.
   PubMed Web of Science ®Google Scholar
• Keating A. How do mesenchymal stromal cells suppress T cells? Cell Stem Cell. 2008;2:106–8.
   PubMed Web of Science ®Google Scholar
• Keating A. Mesenchymal stromal cells. Curr Opin Hematol. 2006;13:419–25.
   PubMed Web of Science ®Google Scholar
• Marigo I, Dolcetti L, Serafini P, Zanovello P, Bronte V. Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol Rev. 2008;222: 162–79.
   PubMed Web of Science ®Google Scholar
• Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood. 2005; 105:1815–22.
   PubMed Web of Science ®Google Scholar
• Nasef A, Mathieu N, Chapel A, Frick J, Francois S, Mazurier C, . Immunosuppressive effects of mesenchymal stem cells: involvement of HLA-G. Transplantation. 2007;84:231–7.
   PubMed Web of Science ®Google Scholar
• Spaggiari GM, Capobianco A, Becchetti S, Mingari MC, Moretta L. Mesenchymal stem cell–natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood. 2006;107:1484–90.
   PubMed Web of Science ®Google Scholar
• Chen JL, Guo ZK, Xu C, Li YH, Hou CM, Mao N, . [Mesenchymal stem cells suppress allogeneic T cell responses by secretion of TGF-beta1]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2002;10:285–8.
   PubMedGoogle Scholar
• Rodriguez AM, Pisani D, Dechesne CA, Turc-Carel C, Kurzenne JY, Wdziekonski B, . Transplantation of a multipotent cell population from human adipose tissue induces dystrophin expression in the immunocompetent mdx mouse. J Exp Med. 2005;201:1397–405.
   PubMed Web of Science ®Google Scholar
• Le Blanc K, Tammik L, Sundberg B, Haynesworth SE, Ringden O. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol. 2003;57:11–20.
   PubMed Web of Science ®Google Scholar
• Le Blanc K, Tammik C, Rosendahl K, Zetterberg E, Ringden O. HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol. 2003;31:890–6.
   PubMed Web of Science ®Google Scholar